The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR congress coverage
Stay up to date with the latest developments in graft-versus-host disease with our live social media coverage from the the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, February 12–16, Honolulu, US.
CONGRESS | #Tandem2025
— GvHD Hub (@gvhd_hub) February 13, 2025
Viktor Arnhold, @MSKCancerCenter, discussed tissue tolerance in refractory GvHD. He suggested a steroid-sparing approach can be safe and efficacious in some patients, and reduce tissue-suppressive side effects. #GvHD pic.twitter.com/QSP8HPImkX
CONGRESS | #Tandem25
— GvHD Hub (@gvhd_hub) February 13, 2025
Kristina Maas-Bauer, Freiburg University, discussed ROCK 1/2 inhibition in GvHD. ROCK inhibition alters the cytokine profile and migration of DCs and macrophages. In addition, ROCK and JAK inhibition can be used together for a synergistic effect. #GvHD pic.twitter.com/LUsKkO3h6b
CONGRESS | #Tandem25
— GvHD Hub (@gvhd_hub) February 14, 2025
Carrie Kitko, @VUMChealth, discussed ruxolitinib, belumosudil, and axatilimab for fibrosis. All have shown to led to clinical improvement in fibrotic organs in GvHD, however complete response is rare. Future studies could focus on combining these agents for… pic.twitter.com/1ySoEh97kO
CONGRESS | #Tandem25
— GvHD Hub (@gvhd_hub) February 14, 2025
Joe Hsu, @StanfordMed discussed new treatments to target BOS in GvHD, including results from the STOP-BOS trial, and preclinical studies of Shc301. Although these treatments have shown promising results, further studies are needed. #GvHD… pic.twitter.com/aoqnQF2Mk0
CONGRESS | #Tandem25
— GvHD Hub (@gvhd_hub) February 14, 2025
Uday Popat, @MDAndersonNews presented results from a phase II study of itacitinib/PTCy/Tac for GvHD prophylaxis in a fractionated busulfan regimen. Low rates of aGvHD and cGvHD were observed with a 1 year GRFS of 69.7%. #GvHDhttps://t.co/7whprdsds2 pic.twitter.com/aReQkV0oQF
CONGRESS | #Tandem25
— GvHD Hub (@gvhd_hub) February 14, 2025
Rachel Salit, @fredhutch, presented results from a phase II study of Rux addition to standard GvHD prophylaxis in pts with MF. aGvHD and cGvHD was reduced in pts who received rux vs standard prophylaxis. NRM and survival were not affected. #GvHD… pic.twitter.com/hABH4C0N1L
CONGRESS | #Tandem25@AshleyHadjis, Hospital of the University of Pennsylvania, discussed associations between #GvHD biomarkers and frailty in older pts undergoing allo-HCT. Regardless of GvHD, higher ST2 levels at 6 months led to worse OS in older pts. https://t.co/7whprdsds2 pic.twitter.com/tNGahaW0PP
— GvHD Hub (@gvhd_hub) February 16, 2025
CONGRESS | #Tandem25 @MunaQayed, @EmoryUniversity discussed the impact of #GvHD on leukemia-free survival. In this study, GvHD did not reduce relapse risk in #ALL or #AML, and severe aGvHD led to inferior OS. https://t.co/7whprdsds2 pic.twitter.com/U1wdexxou8
— GvHD Hub (@gvhd_hub) February 16, 2025
CONGRESS | #Tandem25 @DrMonzrAlMalki @cityofhope presented results from the ACCESS study which assessed PTCy for #GvHD prophylaxis after MMUD PBSC. 1-year OS was 84%, 56% of pts experienced Grade 2-5 infection in the first 100 days post-transplant.https://t.co/7whprdsds2 pic.twitter.com/afCBNqClb3
— GvHD Hub (@gvhd_hub) February 16, 2025
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
